Lyell Immunopharma
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $4 | $2 | $6 | $15 |
Gross Profit | 4 | -2,330 | 6 | 15 |
EBITDA | -42,533 | -21,821 | -138,326 | -36,280 |
EBIT | -44,755 | -24,153 | -140,723 | -38,846 |
Net Income | -44,755 | -24,153 | -140,723 | -38,846 |
Net Change In Cash | 4 | 2 | 6 | 15 |
Free Cash Flow | -34,178 | -38,599 | -32,555 | -28,639 |
Cash | 72,985 | 90,770 | 60,181 | 123,575 |
Basic Shares | 23,364 | 21,876 | 17,093 | 18,268 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $36 | $61 | $130 | $84,683 |
Gross Profit | -11,503 | 61 | 130 | 84,683 |
EBITDA | -262,909 | -200,643 | -214,382 | -165,098 |
EBIT | -274,448 | -220,274 | -234,632 | -183,118 |
Net Income | -274,448 | -342,994 | -234,632 | -183,118 |
Net Change In Cash | 36 | 61 | 130 | 84,683 |
Free Cash Flow | -150,804 | -162,858 | -166,380 | -193,831 |
Cash | 60,181 | 105,597 | 145,647 | 123,554 |
Basic Shares | 17,093 | 13,074 | 12,549 | 12,354 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.92 |
2026-03-31 | -$1.10 |
2025-12-31 | -$7.68 |
2025-09-30 | -$2.13 |